Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Badesch

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Annals of the American Thoracic Society|February 18, 2025
Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)Eric W Robbins, Kaitlin Bradley, David B Badesch, et al.
The European Respiratory Journal|August 30, 2022
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extensionMarc Humbert, Vallerie McLaughlin, J Simon R Gibbs, et al.
Pulmonary Circulation|May 9, 2023
Impact of the COVID-19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association RegistryMegan Mayer, David B Badesch, Kelly H Nielsen, et al.
The European Respiratory Journal|September 11, 2023
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trialRogerio Souza, David B Badesch, H Ardeschir Ghofrani, et al.
American Heart Journal|June 1, 2002
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertensionDavid Langleben, Brian W Christman, Robyn J Barst, et al.
American Journal of Respiratory and Critical Care Medicine|March 4, 2025
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in <i>BMPR2</i> Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)David Montani, Vallerie V McLaughlin, J Simon R Gibbs, et al.
Circulation|June 24, 2004
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshopJohn H Newman, Barry L Fanburg, Stephen L Archer, et al.
The New England Journal of Medicine|March 6, 2023
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionMarius M Hoeper, David B Badesch, H Ardeschir Ghofrani, et al.
The New England Journal of Medicine|September 30, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisVallerie V McLaughlin, Marius M Hoeper, David B Badesch, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 7, 2024
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLARMardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Annals of the American Thoracic Society|February 18, 2025
Medication Nonadherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)Eric W Robbins, Kaitlin Bradley, David B Badesch, et al.
The European Respiratory Journal|August 30, 2022
Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extensionMarc Humbert, Vallerie McLaughlin, J Simon R Gibbs, et al.
Pulmonary Circulation|May 9, 2023
Impact of the COVID-19 pandemic on chronic disease management and patient reported outcomes in patients with pulmonary hypertension: The Pulmonary Hypertension Association RegistryMegan Mayer, David B Badesch, Kelly H Nielsen, et al.
The European Respiratory Journal|September 11, 2023
Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trialRogerio Souza, David B Badesch, H Ardeschir Ghofrani, et al.
American Heart Journal|June 1, 2002
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertensionDavid Langleben, Brian W Christman, Robyn J Barst, et al.
American Journal of Respiratory and Critical Care Medicine|March 4, 2025
Consistent Safety and Efficacy of Sotatercept for Pulmonary Arterial Hypertension in <i>BMPR2</i> Mutation Carriers and Noncarriers: A Planned Analysis of a Phase II, Double-Blind, Placebo-controlled Clinical Trial (PULSAR)David Montani, Vallerie V McLaughlin, J Simon R Gibbs, et al.
Circulation|June 24, 2004
Pulmonary arterial hypertension: future directions: report of a National Heart, Lung and Blood Institute/Office of Rare Diseases workshopJohn H Newman, Barry L Fanburg, Stephen L Archer, et al.
The New England Journal of Medicine|March 6, 2023
Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial HypertensionMarius M Hoeper, David B Badesch, H Ardeschir Ghofrani, et al.
The New England Journal of Medicine|September 30, 2025
Sotatercept for Pulmonary Arterial Hypertension within the First Year after DiagnosisVallerie V McLaughlin, Marius M Hoeper, David B Badesch, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|December 7, 2024
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLARMardi Gomberg-Maitland, David B Badesch, J Simon R Gibbs, et al.
Pageof 9